Introduction {#s1}
============

The ubiquitin-proteasome system (UPS) is vital for cellular homeostasis, acting to regulate protein expression and eradicate oxidized, misfolded proteins. The proteasome is its 2.5-MD catalytic engine---the major cellular protein recycling complex that degrades poly-ubiquitinated substrates ([@bib37]). Its 20S core comprises 28 subunits arranged in four heptameric rings---two outer "alpha" and two inner "beta" rings surround a central pore through which unfolded proteins pass as they are cleaved. Three subunits (six per core) provide a complete spectrum of proteolytic activity after acidic, basic, and hydrophobic amino acids: β1 caspase-, β2 trypsin-, and β5 chymotrypsin-like (encoded by *PSMB6*, *PSMB7*, and *PSMB5*). Proteasome substrate specificity, throughput, and subcellular localization are regulated by activator complexes that dock with the core, forming single- and double-capped holoenzymes. A 19S cap is essential for de-ubiquitination, translocation, and ATP-dependent substrate unfolding. Under normal conditions, 19S-capped 20S core complexes the predominant proteasome species present in the cell ("constitutive" proteasomes). However, in certain conditions, the core can also dock with PA28α/β, PA28γ, and PA200 caps, which lack catalytic activity but widen the 20S pore and increase throughput (reviewed in [@bib20]).

In addition to posttranslational regulation and buffering against proteotoxic stress, the UPS is also the major source of peptides presented to the immune system via MHC class-I molecules. Accordingly, IFN-γ is a potent stimulus for proteasome compositional change. IFN-γ down-regulates constitutive proteasome subunit genes and induces the genes that encode PA28α and PA28β (*PSME1* and *PSME2*) and alternative 20S core subunits β1i, β2i, and β5i (*PSMB9*, *PSMB10*, and *PSMB8*), which increases proteasome throughput and produces a varied repertoire of MHC-I epitopes via different cleavage site preferences ([@bib2]). Hence, in the context of an immunologic challenge, IFN-γ--stimulated cells express a variety of hybrid "immuno(i)-proteasome" complexes.

Proteasome inhibitors (PIs) such as bortezomib and carfilzomib are effective for treatment of multiple myeloma and mantle cell lymphoma. Their clinical activity is partly attributed to disruption of the UPS, which stabilizes apoptotic proteins (e.g., p53 and Bcl2) and IκBα, inhibitor of the NFκB pro-survival pathway. Both inhibitors bind to β5 and β5i subunits, but carfilzomib binds irreversibly and has a favorable side effect profile ([@bib9]). PIs also exploit metabolic addiction to the proteasome. By promoting accumulation of misfolded and oxidized protein aggregates in the ER, they trigger the unfolded protein response (UPR), a sensing mechanism that promotes apoptosis in the event of unsustainably high rates of cellular metabolism ([@bib37]). In cancer, rapid division of cells with mutated genomes *should* incite the UPR, but strategies evolve to cope with proteotoxicity, including proteasome overexpression ([@bib1]). The UPR-inducing activity of PIs is attributed mainly to inhibition of constitutive proteasomes, based on a persisting assumption that this complex is the most abundant in non-hematologic tissues ([@bib32]). However, solid tumors also express the i-proteasome ([@bib3]; [@bib17]), and this could represent an efficient means for maintaining a concentration of toxic protein aggregates below the UPR induction threshold ([@bib36]).

Triple-negative breast cancers (TNBCs) comprise 15--20% of invasive breast carcinomas. They lack clinically significant expression of first-line systemic drug therapy targets (estrogen receptor, human epidermal growth factor receptor-2 \[HER2\]), are typically high-grade, are metabolically active, and often exhibit basal-like and/or mesenchymal phenotypes ([@bib26]; [@bib28]). Cytotoxic chemotherapy is a mainstay of clinical management, but 40--80% of patients still experience distant relapse and premature death, often involving visceral and brain metastases ([@bib14]; [@bib29]). TNBC exhibits considerable molecular and clinical heterogeneity, unsurprising given theirs is a diagnosis of exclusion. Identifying biomarkers and therapeutic targets remain top research priorities. Promising recent developments have centered on exploiting the predictive and therapeutic significance of tumor-infiltrating lymphocytes (TILs). There is now international consensus that the presence and density of TILs in pretreatment diagnostic specimens predicts the response to neoadjuvant chemotherapy and also to second-line treatment where a low-moderate residual disease burden remains ([@bib22]; [@bib23]). Thus, despite the systemic immunosuppression experienced by patients undergoing active treatment, the presence of TILs before this indicates the capacity of the host immune system to synergize with chemotherapy.

In vitro and in vivo studies suggest that the proteasome is a potential therapeutic target in TNBC ([@bib8]; [@bib27]; [@bib41]); however, preliminary clinical data from metastatic patients have been mixed ([@bib43]; [@bib13]; [@bib35]), and these trials pre-dated our understanding of the role of antitumor immunity in TNBC. This study was undertaken to establish the molecular basis of PI activity and relevance to the treatment of breast cancer, incorporating in vitro mechanistic studies with genomic and protein-level data from large human clinical sample cohorts.

Results and Discussion {#s2}
======================

Basal-like breast cancer cell lines are dependent on i-proteasome activity {#s3}
--------------------------------------------------------------------------

We initially characterized the relationship between proteasome subunit expression and sensitivity to chemical or genetic inhibition of the proteasome in vitro. Analysis of breast cancer cell line gene expression data ([@bib25]) indicated significantly higher expression of i-relative to constitutive subunit in basal-A and claudin-low (basal-B) lines than luminal and HER2+ cell lines ([Fig 1A and B](#fig1){ref-type="fig"}). We then performed bortezomib and carfilzomib dose--response assays with a panel of lines that model a range of proteasome subunit levels. Expression of inducible relative to constitutive subunit RNA was anti-correlated with response to both inhibitors ([Figs 1C](#fig1){ref-type="fig"} and [S1A](#figS1){ref-type="fig"}). The relationship to PI sensitivity was most noticeable for *PSMB8* (bortezomib LD~50~ correlation *r* − 0.76, *P* = 0.01), which was also evident at the protein level ([Fig 1D](#fig1){ref-type="fig"}). There was no obvious relationship between bortezomib sensitivity and baseline expression of the proteasome activator cap subunit PA28γ ([Fig 1D](#fig1){ref-type="fig"}). This was not a consequence of preferential i-proteasome inhibition, as the total proteasome activity was suppressed in both MDA-MB-468 (i-prot^high^, low bortezomib LD~50~); and MCF-7 (i-prot^low^, low bortezomib LD~50~) ([Fig 1E and F](#fig1){ref-type="fig"}).

![In vitro analysis of proteasome subunit expression and sensitivity to proteasome inhibitors.\
**(A)** Proteasome subunit expression in breast cancer cell lines ([@bib25]). **(B)** Inducible-to-constitutive subunit expression ratios (i:c) across molecular breast cancer subtypes (stats: two-way ANOVA). **(C)** Linear regression and Pearson correlation analysis of the relationships between i:c and sensitivity to bortezomib or carfilzomib (LD50, lethal dose 50%). Correlation coefficients (r) and regression fit values (r^2^) indicated. **(D)** Western analysis of inducible subunits and the PA28 cap in lines with a range of bortezomib sensitivities. ^\#^MCF10A is a spontaneously immortalized breast-derived line included for comparison. **(E)** Native in-gel proteasome activity assay with lysates from MDA-MB-468 and MCF7 with/without 2-h bortezomib treatment. **(F)** Light microscope images of MDA-MB-468 and MCF7 48 h after bortezomib treatment (captured at 20× magnification, scale bar 50 μm). **(G)** Cell viability after siRNA-mediated depletion of *PSMB8* (i) or *PSMB5* (ii). *P*-values in this figure were from unpaired, two-tailed *t* tests (pair-wise comparisons) or one-way ANOVA tests (comparison across multiple groups): \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001; \*\*\*\**P* \< 0.0001.\
Source data are available for this figure.](LSA-2019-00562_Fig1){#fig1}

![Data supporting [Fig 1](#fig1){ref-type="fig"}.\
**(A)** Proteasome subunit expression in breast cancer cell lines. Gene expression array data from ([@bib25]). **(B, C)** Representative RT-qPCR (B) and Western analysis (C) performed 72 h after siRNA transfection of breast cancer cell lines. NTNC, non-targeted negative control.](LSA-2019-00562_FigS1){#figS1}

To rule out off-target effects, we transfected six lines with *PSMB8*-targeted siRNAs and measured cell viability after 48 h using flow cytometry. With the exception of MDA-MB-231, i-prot^high^ basal lines were significantly more sensitive to *PSMB8* depletion than luminal lines ([Fig 1Gi](#fig1){ref-type="fig"}). MDA-MB-468 (basal/i-prot^high^) and MCF7 (luminal/i-prot^low^) transfected with *PSMB5*-targeted siRNAs showed no significant differences ([Fig 1Gii](#fig1){ref-type="fig"}, with confirmation of RNA and protein knockdown in [Fig S1B and C](#figS1){ref-type="fig"}).

Bortezomib sensitivity correlates with the UPR in vitro {#s4}
-------------------------------------------------------

We reasoned that in cell lines addicted to the i-proteasome, pharmacologic suppression of proteasome activity would cause ER stress and trigger the UPR. Three parallel signaling axes mediate the UPR, initiated by ER-membrane sensors: PRKR-like ER kinase (PERK), activating transcription factor 6α (ATF6α) and inositol-requiring protein 1α (IRE1α). Induction of ATF4 marks PERK activation, whereas the IRE1α branch leads to expression of a specific X-box transcription factor splice isoform, XBP1s, which is associated with UPR-related effects in the nucleus. Collectively, these pathways induce genes required for protein folding, secretion, and clearance, or apoptosis if misfolding cannot be resolved ([Fig 2A](#fig2){ref-type="fig"} \[[@bib40]\]).

![In vitro activation of the unfolded protein response (UPR) by bortezomib in relation to proteasome subunit expression.\
**(A)** Working model of UPR induction by three major signaling axes. BiP, binding immunoglobulin protein (GRP78). **(B)** qRT-PCR for *ATF4* following bortezomib treatment. **(B, C)** Log~2~ fold-change (FC) in *XBP1s*, apoptosis markers, and *NF*κ*B* at multiple time points after bortezomib treatment (B, C: qRT-PCR). **(D)** Inverse association between *PSMB8*/UPR induction and bortezomib sensitivity. **(E)** *PSMB8* qRT-PCR (i) and bortezomib-induced cell death (ii) after pretreatment with IFN-γ. **(F)** IFN-γ--mediated induction of *IRF1* and antigen processing genes in MDA-MB-468/MCF7 cells transfected with scrambled (SCR) or *IRF1*-specific siRNAs. *P*-values in this figure were from unpaired, two-tailed *t* tests: \*\**P* \< 0.01; \*\*\**P* \< 0.001; \*\*\*\**P* \< 0.0001.](LSA-2019-00562_Fig2){#fig2}

In line with our hypothesis, bortezomib treatment induced *ATF4* in the four lines assayed ([Fig 2B](#fig2){ref-type="fig"}). Further analysis of i-proteasome--dependent MDA-MB-468 cells revealed induction of XBP1s within 24 h of treatment, concomitant with apoptosis markers and reduction of pro-survival marker NFκB ([Fig 2C](#fig2){ref-type="fig"}). Thus, *PSMB8*-high, i-proteasome--addicted BC cell lines exhibit UPR-driven apoptosis in response to proteasome inhibition ([Fig 2D](#fig2){ref-type="fig"}). In terms of extrinsic modulation, IFN-γ--induced *PSMB8* in both MDA-MB-468 and MCF7 ([Fig 2Ei](#fig2){ref-type="fig"}), but there was no effect on bortezomib sensitivity ([Fig 2Eii](#fig2){ref-type="fig"}). Assaying key IFN-γ targets after treatment, including the IFN-stimulated response element transactivator *IRF1*, confirmed the IFN-γ-IRF1-STAT1-PSMB8 axis was intact ([Fig 2F](#fig2){ref-type="fig"}). Moreover, siRNA-mediated *IRF1* depletion suppressed target induction ([Fig 2F](#fig2){ref-type="fig"}). Thus, although i-proteasome levels are associated with bortezomib sensitivity, this is not an exclusive determinant. Sensitivity is likely to be linked to functional dependence on the i-proteasome rather than the expression of its components.

i-proteasome induction is associated with the UPR in TNBC {#s5}
---------------------------------------------------------

To explore whether PI therapy is an appropriate strategy for treatment of breast cancer, we mined several large genomic datasets: The Cancer Genome Atlas (TCGA; RNA-sequencing data from 1,092 cases including 176 TNBCs) ([@bib7]), the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC; expression array data from 1,980 cases incl. 333 TNBCs) ([@bib10]), and KM-Plotter, a composite of expression array studies with comprehensive clinical annotation ([@bib15]). We interrogated these datasets to identify patient subgroups that may benefit from PIs and to test the hypothesis that i-proteasome activation is associated with the UPR in human tumors. Meta-analysis of expression data indicated that compared with estrogen receptor-positive (ER+) and HER2+ tumors, TNBCs preferentially express i-proteasome subunit genes over constitutive counterparts (β1i:β1, β2i:β2, and β5i:β5; [Fig 3A](#fig3){ref-type="fig"}), and this is most evident in tumors with a claudin-low phenotype ([Fig 3B](#fig3){ref-type="fig"}).

![i-proteasome genes are induced in claudin-low TNBCs and coordinately expressed with unfolded protein response genes.\
**(A, B)** i:c Subunit expression ratios in breast cancer subtypes (METABRIC data, ANOVA test. \**P* \< 0.05; \*\*\*\**P* \< 0.0001). **(C)** Gene set enrichment analysis plots showing running enrichment scores (ESs) skewed toward the *PSMB8*-correlated transcriptome. NES, normalized ES.](LSA-2019-00562_Fig3){#fig3}

We then performed UPR gene set enrichment analysis ([@bib38]) after ranking the transcriptome according to correlations with *PSMB8*. The distributions of multiple UPR gene sets were skewed toward genes co-expressed with *PSMB8* ([Fig 3C](#fig3){ref-type="fig"}). This was evident in both datasets, specifically in TN, basal-like tumors. *PSMB9* and *PSMB10* were among the top 20 *PSMB8*-correlated genes (*r* 0.89/0.83 and 0.68/0.54 in TCGA/META TNBCs), reflecting coordinated co-expression of i-proteasome subunits. These findings support the idea that i-proteasome addiction could be a therapeutically targetable vulnerability in breast cancer.

i-proteasome switching is driven by gene copy number alterations (CNAs) and stratifies survival in TNBC {#s6}
-------------------------------------------------------------------------------------------------------

*PSMB8* and *PSMB9* genes are located within a 25-Mbp region on chromosome 6p that is frequently affected by CNAs in cancer, specifically, in the class-II locus of the HLA complex, which spans 4 Mbp on chromosome 6p.21 ([Fig 4A](#fig4){ref-type="fig"}). 6p gains are common in high-grade malignancies ([@bib34]), suggesting proteotoxic stress resistance may be a fundamental requirement for cancers with high metabolic activity. TCGA CNA data indicated that 6p is affected by complex genomic instability in TNBC, marked by focal gains and losses ([Fig 4Ai](#fig4){ref-type="fig"}). *PSMB8*/*9* are gained in 46% and amplified in 5.2% of TNBCs. The locus is also gained in ER+ and HER2+ cases, but at lower frequency (17% and 27%; [Fig 4Aii](#fig4){ref-type="fig"}). Flanking *PSMB8/9* are co-altered genes encoding *TAP1* and *TAP2*--ER membrane channels that internalize proteasomal peptides and facilitate MHC class-I antigen presentation ([Fig 4Aii](#fig4){ref-type="fig"}).

![Proteasome gene copy number aberrations related to clinical outcomes in breast cancer.\
**(A)** TCGA 450k methylation array data for chromosome 6. (i) GISTIC calls for each probe shown as fractions of all triple-negative breast cancers (TNBCs). (ii) Zoomed region encoding antigen-processing genes. Fractions of HER2+ and ER+ cases shown for comparison. **(B)** CN status of subunit genes in major disease subtypes. \#, instances of inducible subunit gain and constitutive subunit loss in a large percentage of TNBCs. **(C)** Violin plots showing i:c subunit CN switching (stats: pairwise Kruskal--Wallis tests with Dunn's correction for multiple comparisons; \*\*\*\**P* \< 0.0001). **(D)** Kaplan--Meier analysis of i:c subunit expression in TNBC patients treated with (i) or without (ii) chemotherapy (CT) and/or radiotherapy (XRT). Q4/2-3/1, upper/mid/lower quartiles. Log-rank *P*-values shown. **(E)** i:c subunit expression ratios in TNBC subtypes ([@bib6]): BLIA, basal-like immune-activated; BLIS, basal-like immune-suppressed; LAR, luminal androgen receptor-like; MES, mesenchymal. Kruskal--Wallis test: \*\*\**P* \< 0.001, \*\*\*\**P* \< 0.0001. **(F)** Kaplan--Meier analysis of (i) METABRIC and (ii) TCGA TNBCs classified by whether i-subunit gene copy number outnumbers that of constitutive subunit counterparts. Log-rank *P*-values shown.](LSA-2019-00562_Fig4){#fig4}

Quantifying proteasome subunit gene CNAs across BC subtypes revealed that in addition to gains at 6p21.32 (*PSMB8/9*) in TNBC, other events frequently affecting proteasome subunit CN are losses at 17p13.2 and 16q22.1 (*PSMB6*, *PSMB10*; [Fig 4B](#fig4){ref-type="fig"}). However, the genomic landscape of TNBC is unique in that i-subunit gains occur concomitantly with loss of constitutive subunit genes in more than half of cases ([Fig 4B](#fig4){ref-type="fig"}). This was also evident within individual cases, with 65.3%, 31.2%, and 58.4% of TNBCs exhibiting a predominance of inducible β1, β2, and β5 subunits, respectively ([Fig 4C](#fig4){ref-type="fig"}). Considering that subunit gene copy number is a determinant of overall expression ([Fig S3A](#figS3){ref-type="fig"}), these findings suggest that high i-proteasome expression in TNBC is at least partly a consequence of selection pressure during tumorigenesis.

Next, we used Kaplan--Meier analysis to investigate associations between proteasome subunit expression and patient outcomes. In independent TNBC datasets, i:c subunit expression ratios stratified 10-yr breast cancer--specific survival, but cases with the *highest* i:c ratios had longer survival ([Figs 4D](#fig4){ref-type="fig"} and [S2](#figS2){ref-type="fig"}). Stratification was more prominent among patients treated with chemotherapy and/or radiotherapy ([Figs 4D](#fig4){ref-type="fig"} and [S2](#figS2){ref-type="fig"}). Therefore, althoguh i-proteasome switching subverts metabolic stress in vitro and may confer a selective advantage during TNBC development, in the clinical setting, this seemed to be associated with favorable responses to treatment.

![Data supporting [Fig 2](#fig2){ref-type="fig"}. Relationships between proteasome subunit RNA expression and probability of survival in various subgroups using KM-Plotter datasets.\
**(A, B, C)** i-Proteasome subunits: PSMB8, PSMB9, and PSMB10. **(D, E, F)** c-Proteasome subunits: PSMB5, PSMB6, and PSMB7. (i) Tumors classified as TNBC by IHC (ii, iii, and iv); basal-like cases according to the PAM50 molecular classifier. (ii) All basal-like cases, excluding patients treated with hormone therapy (HT), which are clinically ER+. (iii) Untreated basal-like cases. (iv) Basal-like breast cancers treated with adjuvant and/or neoadjuvant (NA) chemotherapy.](LSA-2019-00562_FigS2){#figS2}

Because (1) the i-proteasome is associated with both metabolic homeostasis and antigen processing (2), multiple antigen-processing machinery components are co-altered by genomic alterations in TNBC, and (3) efficient antigen processing is conducive to antitumor immunity in cancer generally; we reasoned that i-proteasome overexpression could be both a vestige of metabolic addiction *and* indicator of effective antigen presentation. The fact that the link between i-proteasome and clinical outcome is specific to patients treated with chemotherapy, and radiotherapy is consistent with the evidence that these treatments promote immunogenic tumor cell death by reactivating immune surveillance ([@bib11]). Indeed, i-subunit but not c-subunit expression is inversely proportional to tumor purity ([Fig S3B](#figS3){ref-type="fig"}), and the i:c expression ratio is highest in "basal-like, immune-activated" TNBCs ([Fig 4E](#fig4){ref-type="fig"}) characterized by dense lymphocytic infiltrates ([@bib6]).

![Data supporting [Fig 4](#fig4){ref-type="fig"}.\
**(A)** Relationships between subunit CNAs and expression (TCGA data; amp, amplification; del, deletion; dip, diploid; and TPM, transcripts per million). **(B)** Spearman correlation of tumor purity and proteasome subunit expression (from the TGCA BRCA provisional RNAseq dataset \[[@bib7]; [@bib4]\]).](LSA-2019-00562_FigS3){#figS3}

This goes some way to reconciling the i-proteasome's involvement with both tumor development and responses to treatment, but also raises the question of how much of the i-proteasome RNA measured in tumor homogenate is attributable to tumor versus stromal components. Unlike RNA expression, CNAs are intrinsic to the tumor cell compartment, so we performed Kaplan--Meier analysis of TNBCs after classifying them according to shifts in inducible and constitutive proteasome subunit gene copy number. In both METABRIC and TCGA datasets, TNBCs with higher overall i-subunit copy number survived longer after the treatment ([Fig 4F](#fig4){ref-type="fig"}), supporting the idea that higher levels of inducible proteasome subunits are protective.

β5i is a favorable prognostic indicator associated with tumor-specific immunity in TNBC {#s7}
---------------------------------------------------------------------------------------

To validate these findings at the protein level, we performed immunohistochemistry (IHC) analysis of β5i (*PSMB8*) in relation to clinicopathologic variables and disease-specific survival using a third cohort of 424 invasive breast tumors. We also analyzed the MHC--I complex and proteasome activator subunit PA28β (*PSME2*), which is similarly induced by IFN-γ but located outside the HLA complex on chromosome 14q12 and less frequently affected by CNAs (14.5% and 1.7% of TNBCs with *PSME2* gain or amplification; 46% and 5.2% for *PSMB8*). β5i and PA28β were detected in the nuclei and cytoplasm of normal mammary epithelial structures and breast tumor cells, and MHC-I in cytoplasm and cell membranes ([Fig 5A](#fig5){ref-type="fig"} and Tables S1--S3). On average, 83% of cases were strongly positive for β5i, and 17% showed selective loss in the tumor compartment ([Figs 5A](#fig5){ref-type="fig"} and [S4A](#figS4){ref-type="fig"}). Luminal-A--like tumors had the most frequent expression overall, followed by basal-like TNBCs ([Fig S4B](#figS4){ref-type="fig"}). Around one-third of all tumors exhibited loss of MHC-I expression, but again expression was frequently maintained in basal-like TNBCs ([Fig S4C and D](#figS4){ref-type="fig"} and Table S2). For PA28β, 92% of cases were positive, with minimal differences between breast cancer subtypes ([Fig S4E and F](#figS4){ref-type="fig"} and Table S3). Among TNBCs, there was a direct relationship between levels of β5i and PA28β, and they were both strongly associated with expression of MHC-I ([Fig 5B](#fig5){ref-type="fig"}), indicating that overall, there is coordinated expression of MHC-I antigen processing and presentation pathway components in TNBC.

Table S1 Relationships between tumor expression of β5i and clinicopathologic parameters in the Queensland follow-up cohort.

Table S2 Relationships between tumor expression of MHC-I and clinicopathologic parameters in breast cancer.

Table S3 Relationships between tumor expression of PA28β and clinicopathologic parameters in breast cancer.

![Tumor compartment--specific expression of PSMB8 relates to clinicopathologic variables.\
**(A)** Representative β5i, MHC-I, and PA28β IHC analysis of normal breast ducts and lobules (i) and invasive breast tumors (ii, iii), illustrating cases that exemplify maintenance (ii) or selective loss (iii) of these class-I antigen presentation components. Cores are 1.0 mm i.d. and insets 140 μm^2^. **(B)** Contingency analysis of the relationships between β5i, MHC-I, and PA28β in triple-negative breast cancer (TNBC). Fisher's exact test *P*-values indicated \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001. **(C)** Contingency analysis of relationships between β5i, MHC-I, or PA28β, with TILs density (i), TILs PD-L1 positivity (ii), tumor cell PD-L1 positivity (iii), and the density of stromal APCs (sAPCs; iv). Fisher's exact test *P*-values indicated \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001. **(D, E, F)** Kaplan--Meier analysis of TNBCs stratified by β5i, MHC-I, or PA28β (i) or by TIL density after classifying TNBCs by their maintenance or loss of β5i, MHC-I, or PA28β (ii). HR, hazard ratio (95% confidence interval); log-rank *P*-values shown. **(G)** Change in β5i IHC scores in brain metastases (BrM) compared with matching primary breast cancers (BC). Overall numbers of cases exhibiting increases (↑), decreases (↓), or no change (--) are indicated. Paired, two-tailed *t* test *P*-value shown.](LSA-2019-00562_Fig5){#fig5}

![Data supporting [Fig 5](#fig5){ref-type="fig"}.\
**(A, B, C, D, E, F)** Representative IHC images (A, C, E) and chi-squared analysis in key breast cancer subtypes (B, D, F) for β5i (A, B), MHC-I (C, D) and PA28β (E, F). Cores are 1.0 mm i.d. and insets 180 μm^2^. **(G)** Relative proportions of all genes exhibiting copy number change, according to the *PSMB8* copy number status. **(H)** Average number of alterations (single-nucleotide variants \[SNVs\], small deletions, and insertions) per case, according to the *PSMB8* copy number status.](LSA-2019-00562_FigS4){#figS4}

We then reviewed matching hematoxylin and eosin--stained whole sections to quantify immunologic correlates of β5i, PA28β, and MHC-I expression: (1) the density of stromal TILs ([@bib33]), an established marker of treatment response in TNBC ([Fig 5Ci](#fig5){ref-type="fig"}), (2) the frequency of PD-L1 expression by TILs ([Fig 5Cii](#fig5){ref-type="fig"}), and (3) tumor cells ([Fig 5Ciii](#fig5){ref-type="fig"}), a marker of effector T-cell responses in breast cancer ([@bib11]), and (4) the density of stromal cells expressing high levels of MHC-II, a marker of professional APCs (macrophages, dendritic cells, and B-cells; [Fig 5Civ](#fig5){ref-type="fig"}). Contingency analysis showed that TNBCs with sustained expression of β5i and MHC-I were more likely to be infiltrated by TILs and APCs and to exhibit signs of antigen-specific T-cell engagement. These findings are consistent with another report showing a direct relationship between tumor β5i, ER stress markers, MHC-I, and TILs ([@bib21]).

To investigate the potential consequences of i-proteasome components and/or MHC-I being dysregulated or lost in TNBC, we performed the Kaplan--Meier analysis. Expression of β5i or MHC-I modestly stratified survival ([Fig 5Di, Ei, and Fi](#fig5){ref-type="fig"}), but more striking differences began to emerge when we considered the prognostic significance of TILs in the tumor microenvironment of TNBCs that maintained or lost antigen presentation components. TIL density remains the most reliable prognostic indicator in TNBC ([@bib22]; [@bib23]), yet we found that this was specific to tumors that retain expression of β5i, with little difference in outcome over 20 yr among TNBCs that had lost β5i expression ([Fig 5Dii](#fig5){ref-type="fig"}). MHC-I and PA28β showed similar trends, although their interactions with TILs density were not as significant ([Fig 5Eii and Fii](#fig5){ref-type="fig"}). We reasoned that if β5i loss enabled immune escape, expression would be suppressed during metastatic progression. Indeed, IHC analysis of β5i in brain metastases compared with patient-matched primary breast tumor samples revealed lower β5i expression in brain metastases in 16/34 of cases ([Fig 5G](#fig5){ref-type="fig"}; paired *t* test *P* = 0.007).

Taken together, these findings suggest that antigen processing via i-proteasome subunit β5i is associated with antitumor immune responses. Given that we saw such a striking difference in TIL-based prognostication depending on the β5i status, further cohort studies are warranted to investigate predictive testing of i-proteasome expression in conjunction with TILs assessment. We explored the possibility that β5i-high TNBCs might be intrinsically more immunogenic by comparing the mutation burden of *PSMB8* gained versus copy number--neutral TNBCs in the TCGA cohort but found no evidence suggesting that their neoantigen load is higher than other TNBCs ([Fig S4G and H](#figS4){ref-type="fig"}). Hence, β5i expression is unlikely to be causally associated with a dense TIL phenotype, but probably potentiates tumor-specific immune responses providing there is sufficient capacity.

We propose that the i-proteasome is exploited during TNBC development to cope with proteotoxicity, but in immunologically "hot" tumors (defined here as TILs occupying ≥20% of tumor-associated stroma), this ultimately becomes a liability because i-proteasome activity is linked to the efficacy of radiotherapy and chemotherapy ([Fig 6](#fig6){ref-type="fig"}). Hence, adjuvant PI therapy could be counterproductive in TNBC. On the other hand, *increasing* i-proteasome activity could potentiate other first-line therapies. Supporting this idea in principle, Tripathi and colleagues showed that *PSMB8/9* are suppressed in mesenchymal-like non--small cell lung cancers, and that reactivating these genes with exogenous IFN-γ restored a repertoire of MHC-I--bound tumor antigens that could efficiently prime cytotoxic responses from patient-derived peripheral blood mononuclear cells ([@bib39]). 5-Aza-2′-deoxycytidine (decitabine), a cytosine analog and DNA methylation inhibitor, had the same effect by suppressing methylation at *PSMB8/9* enhancers ([@bib39]).

![Model contrasting the potential consequences of i-proteasome expression before and after treatment.](LSA-2019-00562_Fig6){#fig6}

Considering these findings, our study supports the rationale for trialing immunotherapy and DNA methyltransferase inhibitor combinations in TNBC and other solid cancers ([@bib18]). Moreover, we recommend that additional cohort studies are warranted to quantify the prognostic and predictive value of adding β5i IHC to diagnostic assessment of TILs density in TNBC.

Materials and Methods {#s8}
=====================

Cell lines and qRT-PCR {#s9}
----------------------

Cell lines were purchased from the American Type Culture Collection, maintained in recommended culture conditions and regularly screened for Mycoplasma (MycoAlert; Lonza). Cell line working stocks used in this study were authenticated by STR profiling (Promega GenePrint 10 System). For RNA inhibition studies, the cells were transfected in six-well plates (3 × 10^5^ cells/well) with 50 nM siRNAs (GenePharma) using Lipofectamine RNAiMAX (Life Technologies). An IncuCyte live-cell imaging system (Essen BioScience) was routinely used to monitor cell attachment and growth in real time. Expression analyses were performed 72 h post-transfection. For qRT-PCR, total RNA was extracted from cultured cells using the RNeasy Mini Kit (QIAGEN), cDNA was random-primed from 1 μg total RNA (MMLV RT; Life Technologies), and qPCR was performed using SYBR Green (Life Technologies; [Table 1](#tbl1){ref-type="table"}) and a CFX96 instrument (Bio-Rad). Experiments were repeated three times.

###### 

siRNA and primer sequences.

  -------------------------------- ------------------------ --------------------------
  siRNAs                                                    
   PSMB8                           CCACUCACAGAGACAGCUAUU    
   IRF1                            GAAAGUUGGCCUUCCACGUCU    
   PSMB5                           AAGCUCAUAGAUUCGACAUUG    
   Non-targeted negative control   UUCUCCGAACGUGUCACGUTT    
  Primers                                                   
   PSMB6                           CAAGCTGACACCTATTCACGAC   CGGTATCGGTAACACATCTCCT
   PSMB7                           ATCGCTGGGGTGGTCTATAAG    AAGAAATGAGCTGGTTGTCAT
   FOXO3                           TCTTCAGGTCCTCCTGTTCCTG   GGAAGCACCAAAGAAGAGAGAAG
   NOXA                            AGAGCTGGAAGTCGAGTGT      GCACCTTCACATTCCTCTC
   BIM                             GTATTCGGTTCGCTGCGTTC     GCGTTTCTCAGTCCGAGAGT
   CASP3                           TGCTATTGTGAGGCGGTTGT     TCACGGCCTGGGATTTCAAG
   CASP 7                          GTGGGAACGATGGCAGATGA     GAGGGACGGTACAAACGAGG
   BCL2                            GTGAAGTCAACATGCCTGCC     ACAGCCTGCAGCTTTGTTTC
   NFKB                            CGCGCCGCTTAGGAGGGAGA     GGGCCATCTGCTGTTGGCAGT
   PSMB5                           CCGCGCTCTACCTTACCTACCT   GCATGGCTTAATCTTTGAGACAAG
   PSMB8                           CGTCACCAACTGGGACGACA     CTTCTCGCGGTTGGCCTTGG
   IRF1                            AGCTCAGCTGTGCGAGTGTA     TAGCTGCTGTGGTCATCAGG
   STAT1                           CGGGCTCCTTCTTCGGATTC     CAGAGGTAGACAGCACCACC
   XBP1                            TCCTGTTGGGCATTCTGGAC     GGCTGGTAAGGAACTGGGTC
   TAP1                            TAGTCTGGGCAGGCCACTTT     CTCGGAAAGTCCCAGGAACA
   TAP2                            AGTGCTGGTGATTGCTCACA     GAACCAGGCGGGAATAGAGG
   ATF4                            CTTGATGTCCCCCTTCGACC     GAAGGCATCCTCCTTGCTGT
  -------------------------------- ------------------------ --------------------------

Western analysis {#s10}
----------------

Cells were trypsinized, centrifuged, washed, and then lysed in Hepes (100 mM; pH 7.5), EDTA (2 mM), NaF (100 mM), sodium chloride (500 mM), and trypsin inhibitor (50 μg/ml; Promega) with fresh cOmplete Mini Protease Inhibitor (Roche). Protein lysates (5--20 μg) were resolved by SDS--PAGE and probed overnight at 4°C with antibodies against PSMB5 (\#12919), PSMB6 (\#13267), PSMB7 (\#13207), PSMB8 (\#13726), and PA28g (\#2142S) from Cell Signaling, used at 1:1,000, or β-tubulin (SAB4700544, 1:200; Merck). Chemiluminescent detection was carried out using appropriate secondary antibodies conjugated to horseradish peroxidase and the enhanced chemiluminescence kit (Amersham).

Native in-gel proteasome activity assay {#s11}
---------------------------------------

Chymotrypsin-like activity was measured in freshly prepared cell lysates as described previously ([@bib12]) with minor modifications. In brief, 5 × 10^6^ cells were washed three times with ice-cold PBS, pelleted by centrifugation (5 min, 250*g* at 4°C), and then resuspended in lysis buffer (10 mM Tris--HCl \[pH 7.8\], 5 mM ATP, and 5 mM MgCl~2~) and kept on ice for 10 min. The cells were sonicated (MSE ultrasonic disintegrator, amplitude 15, 10 s at 4°C) followed by centrifugation to remove cell debris (5 min, 16,000*g*, 4°C). Whole cell lysates (40 μl) were separated on 3.5% non-denaturing polyacrylamide gels (Bio-Rad) in 10 mM Tris--HCl buffer supplemented with ATP (0.5 mM; Sigma-Aldrich), MgCl~2~ (5 mM), glycerol (10% vol/vol), and DTT (0.5 mM). Electrophoresis was performed at 35 V for 30 min at 4°C, then the voltage was increased to 75 V for 4 h. Peptidolytic activity was detected by incubating gels in Suc-LLVY-MCAc substrate (dissolved in 50 mM Tris \[pH 8.0\], 5 mM MgCl~2~, 1 mM DTT, 2 mM ATP, and 0.02% SDS for 10 min at 37°C). Proteasome bands were identified by the release of highly fluorescent, free 7-amino-3-methylcoumarin (AMC) under UV light (ChemiDoc; Bio-Rad).

In vitro bortezomib/carfilzomib sensitivity assays {#s12}
--------------------------------------------------

A panel of basal-A (BT20 and MDA-MB-468), basal-B (Hs578T and MDA-MB-231) luminal-like (BT-483, MCF7, and T47D), and luminal/HER2+ (SKBr3 and ZR751) cell lines were used for cytotoxicity experiments. The cells were routinely seeded in 96-well plates (2 × 10^4^ cells/well) with varying concentrations of PIs, harvested after 48 h, centrifuged at 1,300*g*, washed in PBS, and stained with 7-amino-actinomycin-D solution (7AAD, 2 μg/ml; Invitrogen) for 10 min at room temperature. Cell viability was determined with a FACSCalibur flow cytometer (Becton Dickinson) and analyzed with FLOWJO software (Tree Star Inc.). Cell survival data were normalized (0--100% defined as minimum and maximum values), and regression analysis was performed using GraphPad Prism software (v8.4) to define LD50 values.

Datasets and statistics {#s13}
-----------------------

The following datasets were used in this study: (1) Affymetrix HG-U133A gene expression array data: n = 51 breast cancer cell lines ([@bib25]), (2) RNASeq (V2 RSEM) mRNA expression z-scores: n = 1,108, provisional TCGA breast tumor dataset ([@bib7]), (3) GISTIC 2.0 putative copy number calls: n = 1,080, provisional TCGA breast tumor dataset ([@bib7]), (4) Illumina HT-12 gene expression array data: n = 1,980, METABRIC invasive breast cancer dataset ([@bib10]), (5) mRNA expression array data: n = 256 TNBCs (IHC classification) and n = 400 basal-like tumors (PAM50 classifier) from KM plotter for breast cancer ([@bib15]), and (6) computationally derived pan-cancer tumor purity assessment of TCGA samples ([@bib4]).

Gene set enrichment analysis was performed using the GSEAPreranked module of GenePattern (weighted scoring scheme, 1,000 permutations) ([@bib31]). Gene sets were extracted from the Gene Ontology Consortium database ([@bib38]) using the search term "UPR." Preparation of graphs and all other statistical tests were performed using GraphPad Prism software (v8.4). Statistical tests are described in figure legends.

Clinical sample cohorts and IHC analyses {#s14}
----------------------------------------

IHC analysis of archival specimens and clinicopathologic data were approved by human research ethics committees at The Royal Brisbane and Women's Hospital (2005-022) and The University of Queensland (2005000785). IHC analyses were performed on two separate cohorts:1. The Queensland follow-up cohort. This resource was built from archival tissue specimens of breast cancer patients treated in Queensland between 1987 and 1992, sourced from the statewide Pathology Service, Pathology Queensland, and sampled in duplicate on tissue microarrays (TMAs). Median follow-up is 13.9 yr (range 0.3--41 yr), median age at diagnosis 59.3 yr, and there were 199 breast cancer--specific deaths at the 25-yr censor point (∼37.7%).2. A second cohort of brain metastases and patient-matched primary breast tumor specimens collected between 2001 and 2013, also sampled in TMAs.

Clinical and pathology data were extracted from diagnostic reports, our internal diagnostic histopathology review (SRL) and the Queensland Cancer Registry. Analysis included cross-referencing to clinicopathologic parameters that were assessed and published previously (e.g., expression of ER, PR, and HER2; histological grade and subtype \[[@bib19]; [@bib44]; [@bib5]; [@bib16]; [@bib24]; [@bib30]; [@bib42]\]). For IHC, 4-μm TMA sections were heat-retrieved in using a Decloaking Chamber and blocked for 15 min at room temperature before staining ([Table 2](#tbl2){ref-type="table"}). The MACH 1 Universal HRP-Polymer Detection Kit was used for detection. Reagents and equipment were from Biocare Medical unless otherwise specified. For image analysis, hematoxylin-counterstained sections were scanned at 40× magnification on an Aperio AT Turbo slide scanner (Leica Biosystems). De-identified digital TMA core images were scored by one assessor and reviewed by a second. The maximum scores of duplicate TMA cores were calculated for each case, except for β5i, MHC-I, and PA28β, where minimum scores were used because the disease-associated phenotypes were a loss of expression. Associations between biomarkers and clinicopathologic variables were investigated using chi-squared, Fisher's exact, and log-rank tests (GraphPad Prism v8.4).

###### 

Immunohistochemistry details.

  Target                Antigen retrieval[^a^](#tblfn1){ref-type="table-fn"}   Primary Ab block           Ab manufacturer and clone                  Primary Ab[^b^](#tblfn2){ref-type="table-fn"}   Scoring[^c^](#tblfn3){ref-type="table-fn"}
  --------------------- ------------------------------------------------------ -------------------------- ------------------------------------------ ----------------------------------------------- --------------------------------------------
  β5i (PSMB8)           Citrate buffer 100°C 20 min                            Background sniper BSA 1%   Cell Signaling \#13726 Mouse IgG1, IA5     1:400 1.5 h, RT                                 Tumor
  PD-L1                 EDTA buffer 95°C 60 min                                Background sniper          Cell Signaling \#13684 Rabbit IgG, E1L3N   1:200 2 h, RT                                   sTILs, tumor
  MHC-II (HLA-DP/Q/R)   Citrate buffer 121°C 5 min                             Goat serum 10% BSA 1%      Abcam \#ab86261 Mouse IgG1, KUL/05         1:100 4°C RT                                    Stroma
  MHC-I (HLA-A/B/C)     Dako retrieval buffer pH 6.0 100°C 10 min              Background sniper BSA 1%   Abcam \#70328 Mouse IgG1, EMR8-5           1:800 1 h, RT                                   Tumor
  PA28 (PSME2)          None                                                   Background sniper BSA 1%   Abcam \#ab183727 Rabbit IgG, EPR14931      1:1,000 1 h, RT                                 Tumor

Citrate buffer: 0.01M citrate buffer, pH 6.0, EDTA buffer: 0.001M Tris--EDTA, pH 8.8.

Primary antibodies diluted in Da Vinci Green Diluent.

TILs were scored on whole breast tumor sections according to the International Working Group criteria ([@bib33]). Intensity and percentage of TILs stained were recorded as a Histo-score. A cut-off of ≥1% was considered positive. BSA, bovine serum albumin; ON, overnight; RT, room temperature.
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